Psoriasis: Risankizumab 'safe and efficacious' over two years

And patients who respond well to the therapy but then withdraw have some residual benefit

Many patients with chronic plaque psoriasis who have responded well to risankizumab are likely to maintain a good response over two years of continuous therapy, according to clinical trial results.